The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation ...
This study determined cryo-EM structures of midnolin-proteasome complexes, providing mechanistic insights to ...
The fireside chats will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event. About Nurix ...
Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million ...
Mitochondria are the small organelles that generate the energy our bodies need to grow, move, and stay healthy. As ...
2d
AI-Designed Drug AH-001 Complete U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability
Discovered Therapeutics; Advances Toward Global Licensing and Phase II Development TAIPEI, Oct. 29, 2025 /PRNewswire/ -- AnHorn Medicines, a biotech company leveraging generative AI to design small ...
Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...
Edited by: Thomas W. Durso and Karen Young Kreeger M. Hochstrasser, "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation," Current Opinion in Cell Biology, 7:215-23, 1995. ...
4don MSN
Why does ALS take away body movement? The hidden burden that seals the fate of motor neurons
ALS, also known as Lou Gehrig's disease, is among the most challenging neurological disorders: relentlessly progressive, ...
New research from the University of Wisconsin–Madison reveals that dysfunction in a protein essential to maintaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback